Table 5.
Univariate analysis of OS in patients with resistance to EGFR-TKIs
| Factor | Beta coefficient | Std Err | P Value | HR value | Lower 95% CI | Upper 95% CI |
|---|---|---|---|---|---|---|
| Age | 0.435 | 0.208 | 0.037 | 1.545 | 1.027 | 2.324 |
| Gender | 0.188 | 0.222 | 0.396 | 1.207 | 0.782 | 1.865 |
| BMI | 0.016 | 0.243 | 0.947 | 1.016 | 0.632 | 1.635 |
| Smoking history | 0.127 | 0.220 | 0.565 | 1.135 | 0.738 | 1.747 |
| ECOG score | 0.081 | 0.216 | 0.708 | 1.084 | 0.710 | 1.655 |
| EGFR mutation type | 0.093 | 0.228 | 0.681 | 1.098 | 0.703 | 1.715 |
| PD-L1 TPS expression | 1.092 | 0.273 | <0.001 | 2.982 | 1.747 | 5.089 |
| Treatment plan | -0.683 | 0.216 | 0.002 | 0.505 | 0.330 | 0.772 |
| NLR | 0.968 | 0.261 | <0.001 | 2.632 | 1.577 | 4.392 |
| PLR | 0.842 | 0.286 | 0.003 | 2.322 | 1.325 | 4.069 |
| LMR | 0.393 | 0.251 | 0.118 | 1.481 | 0.906 | 2.422 |
Note: BMI: Body mass index, ICIs+BCP: immune checkpoint inhibitors plus chemotherapy and antiangiogenic agents, ECOG: Eastern Cooperative Oncology Group, EGFR: Epidermal Growth Factor Receptor, TPS: Tumor Proportion Score, NLR: Neutrophil-to-Lymphocyte Ratio, PLR: Platelet-to-Lymphocyte Ratio, LMR: Lymphocyte-to-Monocyte Ratio, PD-L1: Programmed Death-Ligand 1, TKIs: Tyrosine Kinase Inhibitors, OS: Overall Survival, HR: Hazard Ratio.